Abstract
The title compound, C20H17F3N 2O4, named tasquinimod, is a second-generation oral quinoline-3-carboxamide analogue, which is currently in phase III clinical trials for the treatment of metastatic prostate cancer. The quinoline unit is almost planar (r.m.s. deviation of fitted atoms = 0.0075 Å). The carboxamide side chain, substituted at position 3, is tilted by 88.07 (7)° to the quinoline plane. Both the methyl and carbonyl groups of this carboxamide side chain are in a syn conformation. The 4-(trifluoromethyl)phenyl plane is inclined at 50.62 (17)° to the plane of the carboxamide side chain, and at 87.14 (4)° to the plane of the quinoline ring system. The 4-hydroxy H atom acts as a double proton donor in an intramolecular hydrogen bond to the 5-position methoxy O atom and in an intermolecular contact to the 2-oxo group, generating a chain along [010] in the crystal structure.
Original language | English (US) |
---|---|
Pages (from-to) | o297-o298 |
Journal | Acta Crystallographica Section E: Structure Reports Online |
Volume | 70 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2014 |
Keywords
- Data-to-parameter ratio = 13.2
- Meanσ(C-C) = 0.002 Å
- R factor = 0.044
- Single-crystal X-ray study
- T = 298 K
- wR factor = 0.132
ASJC Scopus subject areas
- Chemistry(all)
- Materials Science(all)
- Condensed Matter Physics